We have combined the powerful functions of IgE and IgG antibodies into a new hybrid antibody class: the IgEGs. IgE and IgG are related but structurally and functionally different antibodies. By fusing the CH2-CH3 domains plus the hinge region of IgG to the C terminus of an IgE molecule, we create an IgEG.
IgEG antibodies are able to bind to both IgE and IgG receptors and can activate a braoder repertoire of immune effector cells than IgG and IgE antibodies alone. IgEG antibodies also combine the long tissue half-life of IgE with elevated serum half-life of IgG offering the potential to lengthen dosing intervals.
In vivo proof of concept has been obtained for the IgEG platform.
